共 50 条
- [31] A Multicenter, Open Label Study of Oral Lenalidomide and Prednisone (RP) Followed by Oral Lenalidomide Melphalan and Prednisone (MPR) and Oral Lenalidomide Maintenance In Newly Diagnosed Elderly Multiple Myeloma PatientsBLOOD, 2010, 116 (21) : 808 - 808Palumbo, AntonioFalco, PatriziaBenevolo, GiuliaRossi, DavideCarella, Angelo MicheleGuglielmelli, TommasinaRocci, AlbertoDe Paoli, LorenzoGrasso, MariellaSiez, Maria Letizia MoscaPiro, EugenioCaltagirone, SimonaGay, FrancescaCavallo, FedericaGaidano, GianlucaBoccadoro, Mario
- [32] Stem Cell (SC) Yield and Transplant with Daratumumab ± Bortezomib, Lenalidomide and Dexamethasone in Transplant-eligible Newly Diagnosed Multiple Myeloma Patients in the Phase 3 PERSEUS StudyCLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S246 - S246Sonneveld, PieterDimopoulos, MeletiosBoccadoro, MarioHang QuachHo, P. JoyBeksac, MeralHulin, CyrilleAntonioli, ElisabettaLeleu, XavierMangiacavalli, SilviaPerrot, AuroreCavo, MicheleBelotti, AngeloBroijl, AnnemiekGay, FrancescaMina, Robertovan de Donk, NielsLiu, YanfangWang, JianpingSitthi-Amorn, Annade Boer, Carla J.Carson, RobinRodriguez-Otero, PaulaBlade, JoanMoreau, Philippe
- [33] Lenalidomide, Adriamycin, and Dexamethasone (RAD) As Induction Therapy for Patients with Newly Diagnosed Multiple Myeloma Who Are Eligible for Autologous Transplantation (ASCT): A Phase 2 Study from the Greek Myeloma Study GroupBLOOD, 2016, 128 (22)Terpos, EvangelosKatodritou, EiriniSymeonidis, ArgirisZagouri, FloraGerofotis, AntonisChristopoulou, GeorgiaGavriatopoulou, MariaChristoulas, DimitriosKourakli, AlexandraKonstantinidou, PavlinaKastritis, EfstathiosDimopoulos, Meletios A.
- [34] Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trialLANCET HAEMATOLOGY, 2023, 10 (10): : E825 - E837Voorhees, Peter M.Sborov, Douglas W.Laubach, JacobKaufman, Jonathan L.Reeves, BrandiRodriguez, CesarChari, AjaiSilbermann, RebeccaCosta, Luciano J.Anderson, Larry D.Nathwani, NityaShah, NinaBumma, NareshEfebera, Yvonne A.Holstein, Sarah A.Costello, CaitlinJakubowiak, AndrzejWildes, Tanya M.Orlowski, Robert Z.Shain, Kenneth H.Cowan, Andrew J.Dinner, ShiraPei, HuilingCortoos, AnnelorePatel, SharmilaLin, Thomas S.Usmani, Saad Z.Richardson, Paul G.
- [35] Interim Analysis of Phase II Study of the Bortezomib-Melphalan-Prednisolone Induction Therapy Followed By Lenalidomide-Plus-Dexamethasone Consolidation and Lenalidomide Maintenance in Non-Transplant Eligible Patients with Newly Diagnosed Symptomatic Multiple Myeloma.BLOOD, 2015, 126 (23)Ishida, TadaoKimura, HideoKubo, KoumeiSunami, KazutakaOzaki, ShujiTakezako, NaokiHanda, HiroshiKosugi, HiroshiMurakami, HirokazuShimizu, Kazuyuki
- [36] Twice-weekly induction with ixazomib-lenalidomide-dexamethasone (IRd) combination followed by extended IRd consolidation and lenalidomide maintenance in transplant-eligible patients with newly diagnosed multiple myeloma: Results of the phase 2 study IFM2014-03BRITISH JOURNAL OF HAEMATOLOGY, 2024, 205 (03) : 891 - 899Perrot, AuroreRoussel, MurielleLauwers-Cances, ValerieHulin, CyrilleLeleu, XavierTouzeau, CyrilleFacon, ThierryMariette, ClaraSchiano, Jean-MarcGay, JulieMontes, LydiaRanta, DanaHuguet, AmandineWuilleme, SorayaDejoie, ThomasDevlamynck, LaureCorre, JillAvet-Loiseau, HerveMoreau, PhilippeAttal, Michel
- [37] Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trialLANCET HAEMATOLOGY, 2022, 9 (11): : E810 - E821Goldschmidt, HartmutMai, Elias K.Bertsch, UtaFenk, RolandNievergall, EvaTichy, DianaBesemer, BrittaDurig, JanSchroers, Rolandvon Metzler, IvanaHaenel, MathiasMann, ChristophAsemissen, Anne M.Heilmeier, BernhardWeinhold, NielsHuhn, StefanieKriegsmann, KatharinaLuntz, Steffen P.Holderried, Tobias A. W.Trautmann-Grill, KarolinGezer, DenizKlaiber-Hakimi, MaikaMueller, MartinKhandanpour, CyrusKnauf, WolfgangScheid, ChristofMunder, MarkusGeer, ThomasRiesenberg, HendrikThomalla, JorgHoffmann, MartinRaab, Marc S.Salwender, Hans J.Weisel, Katja C.
- [38] Outcomes of Post-Induction Bortezomib Therapy in Patients with Newly diagnosed Multiple Myeloma: A Multi-Center Retrospective Observational StudyCLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E296 - E296Luttwak, EfratGatt, MosheLavi, NoaTadmor, TamarKreiniz, NataliaBenyamini, NoamHorowitz, NetanelSuriu, CeliaAvivi, IritTrestman, SvetlanaMittelman, MosheRam, RonRouvio, OryCohen, Yael
- [39] A Phase 2 Study of Extended Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple MyelomaBLOOD, 2021, 138Derman, Ben A.Major, AjayRosenblatt, JacalynAvigan, DavidRampurwala, Murtuza M.Alcantar, LuisLibao, Bernadette M.McIver, AmandaAndreatos, EvangeliaMajor, SarahWolfe, BrittanyGorski, MarthaKarrison, Theodore G.Stefka, AndrewJakubowiak, Andrzej
- [40] A Phase 1/2 Study of Carfilzomib, Iberdomide and Dexamethasone (KID) in Patients with Newly Diagnosed Transplant-Eligible Multiple MyelomaBLOOD, 2023, 142Biran, NoaVesole, David H.Parmar, HarshPhull, PoojaDoucette, KimberlyFeinman, RenaZenreich, JoshuaAnand, PalkaIvanovski, KristinPace, MoniqueBiamonte, LisaCampanaro, MarthaMcClendon, TrinaLimbad, ChandaniBaboolallAracena, SamantaAleman, AdolfoUnawane, RashmiPendergrass, ElizabethLayton, MarieBreeze, GenevieveChappell, AimeeDella Pia, AlexandraKumka, SusanSiegel, David S.